Suppr超能文献

黄嘌呤对气道反应性的多种作用机制。

Multiple mechanisms of xanthine actions on airway reactivity.

作者信息

Howell R E

机构信息

Nova Pharmaceutical Corporation, Baltimore, Maryland.

出版信息

J Pharmacol Exp Ther. 1990 Dec;255(3):1008-14.

PMID:2175791
Abstract

Xanthines are effective in the treatment of asthma, but the mechanism of action remains unclear. Pulmonary effects of seven xanthines, exhibiting a range of potencies as cyclic nucleotide phosphodiesterase (PDE) inhibitors and as adenosine antagonists, were investigated in anesthetized and ventilated guinea pigs. The bronchodilator effects of xanthines, determined from reversal of bronchoconstriction induced by aerosols of histamine and carbachol, correlated with their relative potencies as cyclic AMP-PDE inhibitors. The hypotensive effects of xanthines at bronchodilator doses were also consistent with PDE inhibition. Prophylactic effects of xanthines against bronchoconstriction induced by an aerosol of ovalbumin in sensitized guinea pigs, or by aerosols of leukotriene D4 and platelet-activating factor (PAF) in normal guinea pigs, occurred by a mechanism unrelated to bronchodilation and could not be readily attributed to PDE inhibition or adenosine A1/A2 receptor antagonism. There was a close association between inhibition of the responses to antigen and leukotriene D4, suggesting a common mechanism of action, but these effects gave a different profile from inhibition of the response to PAF. In addition, PAF-induced hypotension was unaffected in animals in which PAF-induced bronchoconstriction was inhibited, suggesting a mechanism other than PAF receptor antagonism. These results indicate that the bronchodilator, antiallergic and anti-inflammatory effects of xanthines occur through multiple molecular mechanisms of action, including at least one unknown mechanism. Furthermore, 8-phenyltheophylline produces these prophylactic effects at a dose that does not produce the cardiovascular or emetic side effects associated with xanthines, thereby exhibiting unique characteristics of potential therapeutic importance.

摘要

黄嘌呤类药物对哮喘治疗有效,但作用机制尚不清楚。研究了七种黄嘌呤类药物对麻醉并通气的豚鼠的肺部效应,这些药物作为环核苷酸磷酸二酯酶(PDE)抑制剂和腺苷拮抗剂表现出不同的效力。黄嘌呤类药物的支气管扩张作用由组胺和气雾剂诱导的支气管收缩逆转来确定,与它们作为环磷酸腺苷 - PDE抑制剂的相对效力相关。黄嘌呤类药物在支气管扩张剂量下的降压作用也与PDE抑制一致。黄嘌呤类药物对致敏豚鼠中卵清蛋白气雾剂或正常豚鼠中白三烯D4和血小板活化因子(PAF)气雾剂诱导的支气管收缩具有预防作用,其作用机制与支气管扩张无关,且不能轻易归因于PDE抑制或腺苷A1/A2受体拮抗。对抗抗原和白三烯D4反应的抑制之间存在密切关联,提示存在共同作用机制,但这些作用与对PAF反应的抑制表现出不同的特征。此外,在PAF诱导的支气管收缩被抑制的动物中,PAF诱导的低血压不受影响,提示存在PAF受体拮抗以外的机制。这些结果表明,黄嘌呤类药物的支气管扩张、抗过敏和抗炎作用通过多种分子作用机制发生,包括至少一种未知机制。此外,8-苯基茶碱以不会产生与黄嘌呤类药物相关的心血管或催吐副作用的剂量产生这些预防作用,从而展现出具有潜在治疗重要性的独特特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验